Objectives: Given that more than 1 million people annually develop isoniazid-resistant tuberculosis (Hr-TB), the issue of Hr-TB may go unnoticed. However, limited studies have focused on the clinical treatment of Hr-TB in China, particularly regarding treatment outcomes and influencing factors. This study aimed to evaluate the treatment outcomes of Hr-TB patients in Shanghai from 2018 to 2021 and analyze the influencing factors, including demographic characteristics, clinical features, and treatment-related factors.
Methods: This study retrospectively reviewed the medical records of Hr-TB patients registered in the TB management information system (TBMIS) from 2018 to 2021. Differences in demographic characteristics, clinical information, and treatment outcomes were evaluated. Multivariable logistic regression was used to identify risk factors associated with unfavorable outcomes.
Results: A total of 664 patients with Hr-TB were included in the analysis. 84 cases (12.7%) had unfavorable outcomes. Only 318 (47.9%) Hr-TB patients used regimens containing fluoroquinolones (FQs). Adverse events occurred in 127 cases (19.1%), of which 12 cases (1.81%) discontinued treatment due to adverse events. There was statistically significant difference in the occurrence of adverse events between the different treatment regimens (P<0.001). Multivariable logistic regression showed that older age (aOR=6.13, 95%CI=1.24-30.24, p=0.026), use of injectable agents (aOR=3.75, 95%CI=1.29-10.94, p=0.016), and treatment duration (95%CI=21.85-1487.61, p<0.001) were risk factors for unfavorable treatment outcomes.
Conclusion: Unfavorable outcomes were more frequent among older patients and those receiving injectable agents among Hr-TB patients in Shanghai, a low-endemic region for TB. This emphasizes the need for timely diagnosis and optimized treatment strategies for isoniazid-resistant tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgar.2025.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stone density can predict the number of ESWL treatments needed in patients with pancreatic duct calculi.
Scand J Gastroenterol
March 2025
Department of Abdominal surgery, Helsinki University Hospital, Helsinki, Finland.
Objectives: Extracorporeal shock wave lithotripsy (ESWL) with endotherapy (ET) is the first-line treatment in patients with chronic pancreatitis (CP) and main pancreatic duct stone (PDS). Our study aimed to evaluate factors that predict the outcome of ESWL in CP patients with PDS.
Methods: We retrospectively analyzed data of 166 patients with CP and radiopaque PDS.
Medication experiences in the treatment of opioid use disorders: Insights from Reddit.
Addiction
March 2025
Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA.
Background And Aims: Better understanding the challenges faced by patients on medications for opioid use disorder (MOUD), including methadone and buprenorphine, is critical to increasing their use/retention. Social media platforms such as Reddit offer a space for patients to share their experiences with medications. We aimed to identify and characterize challenges faced by patients taking MOUD through analysis of discussions from the r/Methadone and r/suboxone subreddits.
View Article and Find Full Text PDFTreat-And-Extend Versus Pro Re Nata Regimen of Intravitreal Conbercept Injection for Neovascular Age-Related Macular Degeneration: Results from COCOA, a Prospective, Open-Label, Multicenter, Randomized Phase IV Clinical Trial.
Semin Ophthalmol
March 2025
Department of Ophthalmology, Peking University People's Hospital, Beijing, China.
Purpose: To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols-a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen-in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).
Methods: Eligible patients, who had not undergone anti-VEGF intraocular injections within 3 months prior to enrollment, were randomly assigned to either the 3+T&E or 3+PRN regimen. The 3+T&E group received at least three monthly injections, with subsequent visit intervals extended based on disease activity assessment.
A population-based cohort study of perinatal mental illness following traumatic brain injury.
Epidemiol Psychiatr Sci
March 2025
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Aims: To examine the risk of perinatal mental illness, including new diagnoses and recurrent use of mental healthcare, comparing women with and without traumatic brain injury (TBI), and to identify injury-related factors associated with these outcomes among women with TBI.
Methods: We conducted a population-based cohort study in Ontario, Canada, of all obstetrical deliveries to women in 2012-2021, excluding those with mental healthcare use in the year before conception. The cohort was stratified into women with no remote mental illness history (to identify new mental illness diagnoses between conception and 365 days postpartum) and those with a remote mental illness history (to identify recurrent illnesses).
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up.
Haematologica
March 2025
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA.
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso-cel or axi-cel per standard of care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!